ARS Pharmaceuticals, Inc. — Director's Dealing 2024

Aug 22, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2024-08-20

Reporting Person: Dorsey Brian (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-08-20	Common Stock	M	50000	$0.64	Acquired	56024	Direct
2024-08-20	Common Stock	S	50000	$15	Disposed	6024	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-08-20	Stock Option (Right to Buy)	$0.64	M	50000	Disposed	2028-11-28	Common Stock (50000)	Direct

Footnotes

F1: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2023.

F2: Immediately exercisable.